JUMP TO CONTENT
Ovarian cancer knot

Standing Strong on Ovarian Cancer Day

Posting date: 08/05/2025
Author: Inside ICON

Standing Strong on Ovarian Cancer Day:    ICON's Commitment to Advancing Care

Ovarian cancer remains one of the most challenging gynaecologic malignancies, both in terms of detection and treatment. Globally, it is the eighth most common cancer in women, with nearly 350,000 new cases reported each year. Despite progress in oncology, survival outcomes remain tightly linked to the timing of diagnosis.

In this article, Martin Lachs, Vice President, Oncology Project Management at ICON, shares his thoughts and insight into ICON’s commitment to supporting innovation, global collaboration, and improved outcomes for women around the world

A Disease Often Detected Too Late

The stark reality of ovarian cancer is its silent progression. Symptoms like bloating, abdominal discomfort, and changes in appetite are vague and often attributed to less serious conditions. As a result, only about 20% of ovarian cancer cases are detected at an early stage. This delay in diagnosis has profound consequences: five-year survival rates can range from as high as 93% when caught early to just 31% when detected late.

This challenge underscores the need for both public awareness and research into better diagnostic tools. Biomarkers, imaging technology, and AI-driven screening methods are all areas of active investigation, but no standard screening method has yet been established for the general population. The lack of early detection tools remains one of the key barriers to improved survival rates.

Hope on the Horizon

Fortunately, treatment options for ovarian cancer have expanded significantly in recent years. One of the most impactful developments has been the introduction of PARP inhibitors, which target cancer cells with BRCA mutations by interfering with their DNA repair mechanisms. Drugs such as olaparib and niraparib have brought real progress for patients with certain genetic profiles.

Martin noted, "Recent treatment advances have included PARP inhibitors, but there are many development programs looking at PD-1 inhibitor combinations and some Antibody Drug Conjugates (ADCs). One of our customers is particularly focused on immunotherapies and ADCs, so we are very excited to be part of their development program." Beyond PARP inhibitors, there is growing interest in immunotherapy and Antibody Drug Conjugates (ADCs). PD-1 and PD-L1 inhibitors, which help restore the immune system's ability to recognize and attack cancer cells, are currently being explored in combination with chemotherapy or targeted agents. 

Although early trials have shown mixed results, researchers are refining patient selection and combination strategies to unlock their full potential. ADCs, on the other hand, offer a highly targeted approach by linking a potent anti-cancer drug to an antibody that seeks out cancer cells. These "smart bombs" promise to deliver powerful effects with fewer side effects, and several ADCs are currently in development for ovarian and other gynaecologic cancers.

ICON's Role in Advancing Research

At ICON, we are proud to contribute meaningfully to this evolving landscape. We are currently supporting development programs focused on immunotherapies and ADCs, working closely with leading biopharmaceutical sponsors. Our experience in oncology clinical trials—particularly in gynaecologic cancers—positions us as a key partner in the global fight against ovarian cancer. Martin emphasized, "ICON is highly engaged with the global Investigator community in gynaecologic/ovarian oncology research. We have made important contributions to 13 ovarian cancer studies where many patients from North America & EMEA have participated in our ovarian cancer trials." Collaborating with the World's Leading Cooperative Groups A cornerstone of our success is our close collaboration with respected research networks such as ENGOT (European Network for Gynaecological Oncological Trials) and GOG (Gynaecologic Oncology Group). These organizations are instrumental in running high-quality clinical trials and have been central to many of the advances in ovarian cancer care.

Martin shared, "ICON’s excellent delivery of ovarian cancer studies is strongly correlated with our engagement with co-operative groups, like ENGOT covering Spain, Italy, France, Czech Republic, UK, Israel or GOG covering USA and Canada. ICON is proud of our strong experience in engaging with these co-operative groups and the difference we are trying to bring to the lives of patients and their families."

ENGOT brings together trial groups from multiple countries including Spain, Italy, France, the Czech Republic, the UK, and Israel, while GOG covers sites across the USA and Canada. Our long-standing partnerships with these groups help ensure that studies are executed efficiently and ethically, while staying deeply connected to local investigators and patients.

By aligning with ENGOT and GOG, ICON facilitates research that is both global in scope and locally relevant. We are able to leverage these networks to streamline patient recruitment, support investigator engagement, and uphold the highest standards in data quality and patient safety.

Why Our Work Matters

Every clinical trial represents more than data points. It represents a chance for a patient to access cutting-edge treatment, a family to find hope, and a community to move closer to a cure. At ICON, we never lose sight of the people behind the protocols. Our focus on collaboration, quality, and compassion drives our mission to improve patient outcomes.

We are especially proud of our efforts to foster inclusion in clinical trials, ensuring women from varied backgrounds and regions have access to potentially life-changing treatments. With every study we support, we strive to close the gap between medical research and the real-world needs of patients and caregivers.

Looking to the Future

The fight against ovarian cancer is far from over, but progress is being made every day. Through our partnerships, scientific expertise, and unwavering dedication, ICON continues to push boundaries and make a meaningful difference in women’s health.

This Ovarian Cancer Day, we honour the courage of patients, the dedication of researchers, and the power of collaboration. We remain steadfast in our commitment to helping bring forward the next generation of therapies that will transform lives.

Join Us in Making a Difference

Whether you are a clinician, researcher, or someone passionate about advancing healthcare, ICON offers opportunities to contribute to this important mission. Together, we can ensure that innovation reaches the women who need it most - faster, safer, and more effectively. 

View our current job openings at ICON today.

List #1

Related jobs at ICON

Clinical Research Associate II

Salary

Location

China

Department

Clinical Monitoring

Location

China

Remote Working

Home-Based

Business Area

ICON Strategic Solutions

Job Categories

Clinical Monitoring

Job Type

Permanent

Description

As a Clinical Research Associate you will be joining the world’s largest & most comprehensive clinical research organisation, powered by healthcare intelligence.

Reference

2025-120324

Expiry date

01/01/0001

Allen Hao

Author

Allen Hao
Allen Hao

Author

Allen Hao
Read more Shortlist Save this role
Senior Clinical Research Associate

Salary

Location

Beijing

Department

Clinical Monitoring

Location

Beijing

Business Area

ICON Strategic Solutions

Job Categories

Clinical Monitoring

Job Type

Permanent

Description

As a CRAII you will be joining the world’s largest & most comprehensive clinical research organisation, powered by healthcare intelligence.

Reference

2025-118386

Expiry date

01/01/0001

Irena Guo

Author

Irena Guo
Irena Guo

Author

Irena Guo
Read more Shortlist Save this role
Clinical Research Coordinator

Salary

Location

US, Wilmington, NC

Location

Wilmington

Remote Working

Office Based

Business Area

ICON Full Service & Corporate Support

Job Categories

Clinical Research Site Services

Job Type

Permanent

Description

Title: CRC Level I (Clinical Research Coordinator)Location: On-Site (Wilmington NC)Summary: The CRC ensures the safety of our volunteers, promotes the mission of Accellacare, and strives to meet and e

Reference

JR132233

Expiry date

01/01/0001

Sasha Brown

Author

Sasha Brown
Sasha Brown

Author

Sasha Brown
Read more Shortlist Save this role
Clinical Research Coordinator - Level 1

Salary

Location

US, Raleigh, NC, 27609

Location

Raleigh

Remote Working

Office Based

Business Area

ICON Full Service & Corporate Support

Job Categories

Clinical Research Site Services

Job Type

Permanent

Description

We have an incredible opportunity for a Clinical Research Coordinator 1 to join ICON’s Accellacare team. The CRC ensures the safety of our volunteers, promotes the mission of Accellacare, and strives

Reference

JR131919

Expiry date

01/01/0001

Tallulah Pierre Read more Shortlist Save this role
View all
List #1

Related stories

Female scientist with microscope
What is Real World Evidence?

Teaser label

Industry

Content type

Blogs

Publish date

07/21/2025

Summary

What is Real World Evidence? Understanding its Role in Clinical Research Real World Evidence (RWE) is a term increasingly being used within the healthcare and pharmaceutical industries, shaping cr

Teaser label

Discover what Real World Evidence (RWE) is, and how it’s transforming clinical research.

Read more
Two medics at ICON clinical research clinic
The Strategic Role of Site Selection and Activation in Clinical Trials

Teaser label

Industry

Content type

Blogs

Publish date

07/07/2025

Summary

Precision at the Outset: The Strategic Role of Site Selection and Activation in Clinical Trials The success of any clinical trial begins well before the first patient is enrolled. Behind every sit

Teaser label

Explore the critical role of site selection and activation in clinical trials.

Read more
3 x Digital padlocks
The Role of Cybersecurity in Clinical Data Management

Teaser label

Industry

Content type

Blogs

Publish date

07/04/2025

Summary

Cybersecurity in Clinical Data Management In clinical research, data is both a vital asset and a significant responsibility. As trials become increasingly digitised and decentralised, the protectio

Teaser label

Learn about the critical role cybersecurity plays in an increasingly digital research environment.

Read more
View all
List #1

Recently viewed jobs

View Jobs

Browse popular job categories below or search all jobs above